Regeneron Pharmaceuticals, Inc.
REGN
$893.19
$0.7050.08%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -8.87% | -25.68% | -24.40% | -47.28% | -46.28% |
| Total Depreciation and Amortization | 23.32% | 29.23% | 33.37% | 25.08% | 19.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -45.80% | -50.56% | -87.11% | -33.81% | -9.10% |
| Change in Net Operating Assets | 61.32% | 135.62% | -110.92% | -49.05% | 87.30% |
| Cash from Operations | -8.39% | -7.82% | -43.93% | -49.72% | -29.18% |
| Capital Expenditure | -21.78% | -4.49% | -0.41% | -8.32% | -6.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 76.16% | 77.81% | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.64% | -38.17% | 35.69% | 73.26% | 38.66% |
| Cash from Investing | 15.84% | -26.32% | 34.74% | 61.61% | 29.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -24.61% | -27.97% | -42.21% | -29.34% | -9.14% |
| Repurchase of Common Stock | -16.10% | 16.35% | -15.50% | -7.69% | 5.59% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -77.41% | 4.58% | -242.41% | -142.94% | -0.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -272.44% | -2,344.74% | -210.20% | -70.16% | -67.96% |
